Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Demecarium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 17/20 | 0.70 |
| ▸ | BCHE | P06276 | 4/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demecarium SCHEMBL34283 | 1.00 | ACHE (0.70) | ACHEBCHELMNAMEN1KMT2A | |
| Demecarium SCHEMBL61421 | 0.99 | ACHE (0.69) | ACHEBCHELMNAMEN1KMT2A | |
| Demecarium SCHEMBL31649032 | 0.99 | ACHE (0.69) | ACHEBCHELMNAMEN1KMT2A | |
| Demecarium SCHEMBL2253116 | 0.87 | ACHE (0.54) | ACHEBCHELMNAMEN1KMT2A | |
| SCHEMBL12043598 | 0.85 | ACHE (0.73) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL29618009 | 0.83 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL41128 | 0.83 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL34419 | 0.81 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL8026154 | 0.81 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL29603805 | 0.81 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3413872-B1 | NON-INVASIVE OCULAR DRUG DELIVERY INSERT TECHNOLOGY | UNIV DE COIMBRA (PT) | 2024-10-02 | — | — | EP | claimed |
| US-20260007131-A1 | HERBICIDAL COMPOSITION CONTAINING DIFLUOROBUTENOIC ACID AMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2026-01-08 | — | — | US | disclosed |
| EP-4552496-A1 | HERBICIDAL COMPOSITION CONTAINING DIFLUOROBUTENE ACID AMIDE COMPOUND | Ishihara Sangyo Kaisha, Ltd. (JP) | 2025-05-14 | — | — | EP | disclosed |
| CN-119325339-A | Comprising difluorobutenamide herbicidal composition of compounds | 石原产业株式会社 | 2025-01-17 | — | — | CN | disclosed |
| CN-116178575-B | Collybia albuminosa polysaccharide, and preparation method and application thereof | 暨南大学 | 2024-03-08 | — | — | CN | disclosed |
| CN-117377764-A | Multivalent oligonucleotide reagents and methods of use thereof | 中美瑞康核酸技术(南通)研究院有限公司 | 2024-01-09 | — | — | CN | disclosed |
| WO-2023238718-A1 | HERBICIDAL COMPOSITION CONTAINING DIFLUOROBUTENE ACID AMIDE COMPOUND | 石原産業株式会社 | 2023-12-14 | — | — | WO | disclosed |
| US-20230295243-A1 | COMPOSITION AND METHOD FOR TREATING EYE DISEASES | FTGEN Corp | 2023-09-21 | — | — | US | disclosed |
| EP-4185333-A1 | COMPOSITION AND METHOD FOR TREATING EYE DISEASES | Frontera Therapeutics, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| CN-116178575-A | Collybia albuminosa polysaccharide, and preparation method and application thereof | 暨南大学 | 2023-05-30 | — | — | CN | disclosed |
| CN-111217667-B | Synthetic method of tetrabromocyclooctane | 山东润科化工股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| US-20220061324-A1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA CROP PROTECTION AG (CH) | 2022-03-03 | — | — | US | disclosed |
| CN-114126661-A | Biological materials and methods related thereto | 奥克兰服务有限公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2022018516-A1 | COMPOSITION AND METHOD FOR TREATING EYE DISEASES | INSPIRAR LIMITED (CN) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220061324-A1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | DDT, ACHE, AADAC | ACHE 2/4885BCHE 250/4885LMNA 4474/4885 |
| US-20260007131-A1 | HERBICIDAL COMPOSITION CONTAINING DIFLUOROBUTENOIC ACID AMIDE COMPOUND | DDT, CBR1, DHCR24 | ACHE 1219/4885BCHE 644/4885LMNA 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.